Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

References

• WolmarkNWangJMamounasEBryantJFisherBPreoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18J Natl Cancer Inst Monogr2001309610211773300
   PubMedGoogle Scholar
• KaderYAEl-NahasTSakrAAdjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimensOnco Targets Ther201361073107723966793
   PubMed Web of Science ®Google Scholar
• ParkSOYooYBKimYHEffects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7Ann Surg Treat Res2015882556225692115
   PubMed Web of Science ®Google Scholar
• RochéHFumoleauPSpielmannMSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialJ Clin Oncol200624365664567117116941
   PubMed Web of Science ®Google Scholar
• AndreFBroglioKRocheHEstrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysisJ Clin Oncol200826162636264318509176
   PubMed Web of Science ®Google Scholar
• MazouniCKauSWFryeDInclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancersAnn Oncol200718587488017293601
   PubMed Web of Science ®Google Scholar
• GuarneriVBroglioKKauSWPrognostic value of patho-logic complete response after primary chemotherapy in relation to hormone receptor status and other factorsJ Clin Oncol20062471037104416505422
   PubMed Web of Science ®Google Scholar
• SparanoJAWangMMartinoSWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med2008358161663167118420499
   PubMed Web of Science ®Google Scholar
• García-MartínezEGilGLBenitoACTumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancerBreast Cancer Res201416648825432519
   PubMed Web of Science ®Google Scholar
• IshidaTKibaTTakedaMPhase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overex-pressing metastatic breast cancers resistant to both anthracyclines and taxanesCancer Chemother Pharmacol200964236136919082596
   PubMed Web of Science ®Google Scholar
• KibaTMoriiNTakahashiHPathological complete response rate in hormone negative breast cancer patients treated with neoadjuvant FEC and weekly paclitaxel: A case series and review of the literatureOncol Lett2015
   Web of Science ®Google Scholar
• YanagawaMIkemotKKawauchiSLuminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotypeBMC Res Notes2012537622830453
   PubMedGoogle Scholar
• KurosumiMAkashi-TanakaSAkiyamaFHistopathological criteria for assessment of therapeutic response in breast cancer (2007 version)Breast Cancer20081515718224386
   PubMed Web of Science ®Google Scholar
• AomatsuNYashiroMKashiwagiSCD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancerPLoS One201279e4586523049880
   PubMed Web of Science ®Google Scholar
• RouzierRPerouCMSymmansWFBreast cancer molecular subtypes respond differently to preoperative chemotherapyClin Cancer Res200511165678568516115903
   PubMed Web of Science ®Google Scholar
• PapadimitriouKArdavanisAKountourakisPNeoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments’ armamentariumJ Thorac Dis20102316017022263038
   PubMedGoogle Scholar
• KaufmannMvon MinckwitzGBearHDRecommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Ann Oncol200718121927193417998286
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMMeta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC)Cancer Res201272Suppl Abstract nr S1–S11
   Google Scholar
• MartinMPienkowskiTMackeyJAdjuvant docetaxel for node-positive breast cancerN Engl J Med2005352222302231315930421
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• BlowsFMDriverKESchmidtMKSubtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesPLoS Med201075e100027920520800
   PubMed Web of Science ®Google Scholar
• de RondeJJHannemannJHalfwerkHConcordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy responseBreast Cancer Res Treat2010119111912619669409
   PubMed Web of Science ®Google Scholar
• KimSISohnJKooJSParkSHParkHSParkBWMolecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancerOncology2010795–632433021430399
   PubMed Web of Science ®Google Scholar
• KimHSParkIChoHJAnalysis of the potent prognostic factors in luminal-type breast cancerJ Breast Cancer201215440140623346168
   PubMed Web of Science ®Google Scholar
• PeintingerFSymmansWFGonzalez-AnguloAMThe safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapyCancer200610761248125416862596
   PubMed Web of Science ®Google Scholar
• ThomasAOhlingerRHauschildMMusteaABlohmerJUKümmelSOptions and limits of surgery after pre-operative chemotherapy in breast cancerAnticancer Res2006262C1677168216617561
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• HallECameronDWatersRComparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)Eur J Cancer201450142375238925065293
   PubMed Web of Science ®Google Scholar